E 6201

Drug Profile

E 6201

Alternative Names: E6201

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eisai Medical Research
  • Developer Eisai Co Ltd; Strategia Therapeutics; University of Arizona; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Lactones; Resorcinols
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; MAP kinase kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase I Brain metastases; Solid tumours
  • Discontinued Plaque psoriasis

Most Recent Events

  • 02 Jul 2018 Phase-I clinical trials in Brain metastases in USA (IV) (NCT03332589)
  • 24 Jun 2018 Biomarkers information updated
  • 09 Nov 2017 Strategia Therapeutics and University of Arizona plan a phase I trial for Brain metastases and Malignant melanoma (Metastatic disease) in USA in January 2018 (NCT03332589)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top